114 related articles for article (PubMed ID: 11307156)
1. Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia.
Smeyne M; Goloubeva O; Smeyne RJ
Glia; 2001 Apr; 34(2):73-80. PubMed ID: 11307156
[TBL] [Abstract][Full Text] [Related]
2. Glia cell number modulates sensitivity to MPTP in mice.
Smeyne M; Jiao Y; Shepherd KR; Smeyne RJ
Glia; 2005 Nov; 52(2):144-52. PubMed ID: 15920722
[TBL] [Abstract][Full Text] [Related]
3. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
Ito T; Suzuki K; Uchida K; Nakayama H
Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the time courses of selective gene expression and dopaminergic depletion induced by MPP+ in MN9D cells.
Wang J; Duhart HM; Xu Z; Patterson TA; Newport GD; Ali SF
Neurochem Int; 2008 May; 52(6):1037-43. PubMed ID: 18069091
[TBL] [Abstract][Full Text] [Related]
5. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
Aoki E; Yano R; Yokoyama H; Kato H; Araki T
Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
[TBL] [Abstract][Full Text] [Related]
6. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
7. AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Choi JS; Park C; Jeong JW
Biochem Biophys Res Commun; 2010 Jan; 391(1):147-51. PubMed ID: 19903456
[TBL] [Abstract][Full Text] [Related]
8. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
9. Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.
Cano-Jaimez M; Pérez-Sánchez F; Milán M; Buendía P; Ambrosio S; Fariñas I
Neurobiol Dis; 2010 Apr; 38(1):92-103. PubMed ID: 20079841
[TBL] [Abstract][Full Text] [Related]
10. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
Lau YS; Novikova L; Roels C
Neurosci Res; 2005 Aug; 52(4):371-8. PubMed ID: 15936837
[TBL] [Abstract][Full Text] [Related]
11. MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Viaggi C; Vaglini F; Pardini C; Caramelli A; Corsini GU
Neuropharmacology; 2009 Jun; 56(8):1075-81. PubMed ID: 19298832
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.
McLaughlin P; Zhou Y; Ma T; Liu J; Zhang W; Hong JS; Kovacs M; Zhang J
Glia; 2006 Apr; 53(6):567-82. PubMed ID: 16419087
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
14. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
[TBL] [Abstract][Full Text] [Related]
15. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
[TBL] [Abstract][Full Text] [Related]
16. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
Faherty CJ; Raviie Shepherd K; Herasimtschuk A; Smeyne RJ
Brain Res Mol Brain Res; 2005 Mar; 134(1):170-9. PubMed ID: 15790541
[TBL] [Abstract][Full Text] [Related]
17. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation.
Li R; Peng N; Du F; Li XP; Le WD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Apr; 26(4):376-80. PubMed ID: 16624731
[TBL] [Abstract][Full Text] [Related]
20. Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures.
Di Monte DA; Schipper HM; Hetts S; Langston JW
Glia; 1995 Oct; 15(2):203-6. PubMed ID: 8567072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
